Global Information
회사소개 | 문의

세계의 바이오시뮬레이션 기술 시장

Biosimulation Technology

리서치사 Global Industry Analysts, Inc.
발행일 2015년 09월 상품 코드 341978
페이지 정보 영문 164 Pages
가격
US $ 4,500 ₩ 5,045,400 PDF by E-mail (Single user license) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 13,500 ₩ 15,136,200 PDF by E-mail (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 바이오시뮬레이션 기술 시장 Biosimulation Technology
발행일: 2015년 09월 페이지 정보 : 영문 164 Pages

한글목차

세계의 바이오시뮬레이션(Biosimulation) 기술 시장에 대해 조사했으며, 미국, 캐나다, 일본, 유럽, 아시아태평양 지역, 라틴아메리카 및 기타 지역 등의 지역별 분석, 2013-2020년 매년 실적/추정 및 예측, 주요 기업 및 니치 기업 42사 개요 등의 정보를 전해드립니다.

제1장 서론, 조사 방법, 제품 정의

  • 조사 신뢰성과 보고서 제약
  • 면책사항
  • 데이터 분석과 보고서 작성 수준
    • 정량 기법 및 분석법
  • 제품 정의와 조사 범위

제2장 주요 요약

  • 산업 개요
    • 바이오시뮬레이션 : 약제 연구개발에 큰 이점
    • 현재 및 향후 분석
    • 응용 분야와 최종사용자 분야
    • 바이오시뮬레이션은 약제 개발 패러다임의 변화를 제공
    • 주요 시장 발전 촉진요인의 개요
    • 시장 발전 저해요인
    • 경쟁
  • 시장 발전 촉진요인
    • 의료비 증가가 Drug Discovery and Development의 요구를 촉진
    • CDD 발생 건수 및 유병률 증가 : 주요 발전 촉진요인
    • 세계적인 인구 고령화가 첨단 약제의 연구 개발을 촉진
    • 기존 Drug Discovery와 관련된 높은 비용
    • 후기 임상시험의 높은 실패율
    • 최근의 후기 임상시험 실패 사례 리스트(2014년)
    • 중국과 인도 : 연구 개발 투자의 핫스팟
    • 바이오시뮬레이션은 소아과 약제 개발의 과제를 극복
  • 시장 동향 : 통찰
    • 시뮬레이션 툴은 증가하는 생명과학 연구개발 예산에 대한 압력을 없앤다
    • 바이오시뮬레이션은 신경변성 질환을 한계로부터 벗어나게 한다
    • 당뇨병 연구의 새로운 길을 나타낸다
    • 바이오시뮬레이션은 개발 지원에서 임상 툴로 이동
    • 폐 바이오시뮬레이션 : OIP 개발에 변혁을 가져온다
    • Drug Repositioning용 바이오시뮬레이션
    • 그리드 기반 도킹이 바이오시뮬레이션을 지원
    • 보다 우수한 모델의 필요성 : 시장 혁신을 촉진하는 주요 요인
  • 기술 개요
    • 바이오시뮬레이션 : 간단한 소개
    • Drug Discovery and Development
    • 약제 개발 프로세스의 각 단계
    • Drug Discovery 기술
    • 인체생리학
    • 수학적 모델과 바이오시뮬레이션 기법
    • 보텀업 모델링
    • 톱다운 모델링
  • 제품 발표/인가
  • 최신 산업 동향
  • 주요 국제 기업
  • 세계 시장 전망

제3장 시장

  • 미국
  • 캐나다
  • 일본
  • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 스페인
    • 러시아
    • 기타 유럽
  • 아시아태평양 지역
  • 라틴아메리카
  • 기타 지역

제4장 경쟁 구도

KSM 15.10.30

영문목차

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.
Biovia
Certara L.P
Chemical Computing Group
Entelos, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biosimulation: Massively Benefiting Drug R&D
  • Current and Future Analysis
  • Application and End-user Areas
    • Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)
    • Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)
  • Biosimulation Offers Paradigm Shift in Drug Development
  • Key Market Drivers in a Nutshell
  • Market Restraints
  • Competition

2. GROWTH DRIVERS

  • Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development
    • Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
    • Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
    • Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)
    • Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Aging Global Population Drives Advanced Drug R&D
    • Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • High Costs Associated with Traditional Drug Discovery
    • Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
    • Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)
  • High Failure Rate of Late-Stage Drug Trials
  • List of Recent Late-stage Drug Failures (2014)
  • China and India: Hot Spots for R&D Investment
    • Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)
  • Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS - AN INSIGHT

  • Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets
    • Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)
  • Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
  • Marking New Avenues in Diabetes Research
  • Biosimulation Moving From Discovery Aid to Clinical Tool
  • Lung Biosimulation: Game Changer for OIP Development
  • Biosimulation for Drug Repositioning
  • Grid-based Docking Aids Biosimulation
  • Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

  • Biosimulation - A Brief Introduction
  • Drug Discovery and Development
  • Stages in Drug Development Process
    • Target identification
    • Target Validation
    • Lead Identification
    • Lead Optimization
    • Pre-Clinical Testing
    • Clinical Trials
  • Drug Discovery Technologies
  • Human Physiology
  • Mathematical Models and Biosimulation Technique
  • Bottom-up Modeling
  • Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

  • Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0
  • Optimata Granted US Patent for Biosimulation Technology
  • Cognigen Releases Version 1.3 of KIWI™
  • Simulations Plus Releases Version 9.0 of GastroPlus™
  • Certara Launches Version 2.0 of Cardiac Safety Simulator
  • Certara Releases Version 14 of Simcyp™ Simulator
  • Certara Receives FDA Grant for MechDermA
  • Physiomics Launches EasyAP™
  • Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
  • Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

  • Certara Merges Its Pharsight Consulting with Quantitative Solutions
  • Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
  • Physiomics Signs Contract with Merck Serono
  • PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions
  • CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
  • Dassault Systemes Acquires Accelrys
  • Rhenovia Pharma Secures Series B Funding
  • Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
  • Arsenal Capital Partners Acquires Certara
  • Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Advanced Chemistry Development, Inc. (Canada)
  • Biovia (Formerly Accelrys) (US)
  • Certara L.P. (US)
  • Chemical Computing Group (Canada)
  • Entelos, Inc. (US)
  • In Silico Biosciences, Inc. (US)
  • InhibOx (UK)
  • Insilico Biotechnology AG (Germany)
  • LeadInvent Technologies (India)
  • Leadscope, Inc. (US)
  • Nimbus Therapeutics (US)
  • OpenEye Scientific Software Inc. (US)
  • Physiomics Plc. (UK)
  • Rhenovia Pharma SAS (France)
  • Schrodinger, LLC (US)
  • Simulations Plus, Inc.(US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Biosimulation to Abate Life Sciences R&D Spending
    • Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)
    • Ageing Population - Booster for Effective Drug Development
    • Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Rise in Chronic Disorders Drive Market Growth
    • Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)
    • Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)
    • Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Increasing Incidence of Cancer: A Major Growth Driver
    • Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Demand for Advanced Drug Development
    • Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Regulatory Authorities Stress on Paradigm Shift in Drug Development
    • Ageing Population Boosts Demand
    • Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Rhenovia Pharma SAS - A Key Player
  • B. Market Analytics
    • Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Insilico Biotechnology AG - A Key Player
  • B. Market Analytics
    • Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Growing Population and Aging Demographic Drive Demand for Advanced Drug Development
    • Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
    • Leadinvent Technologies (India) - A Key Player
  • B. Market Analytics
    • Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research